IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Learn how to tell the difference between these two common symptoms.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

A woman is accused of stealing thousands of dollars’ worth of her mother’s lung cancer medication. According to the Wentzville Police Department, the alleged theft happened on Feb. 25 at the mother’s ...

Inside a cavernous hall at the Swiss-French border, the air hums with high voltage and possibility. From his perch on the ...

Health Notes is an occasional listing of health happenings around Louisiana. Have something you'd like to share? Contact us at margaret.delaney@theadvocate.com.

The experience features surgical robotic technology designed to assist with lung cancer diagnosis and treatment. Lung cancer is often found in patients aged 65 and older. Dr. Angel Nunez, a ...

Costochondritis is not cancer, but its symptoms can resemble those of some types of cancer. It can also develop after certain ...

The trial will include patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.